31.12.2014 - NeuroDerm shares rose after the publication of a new drug research

The stock price of NeuroDerm shows a significant increase against the background of statements by representatives of the company on promising results of a trial of treatment of Parkinson's disease. Certification and production of the drug can bring the company significant profits. These drugs may be more effective than surgery and more accessible to patients. Let us recall that the company's shares went public in November. We recommend buying the stocks.

RISK WARNING: Trading of complex financial products, such as Stocks, Futures, Foreign Exchange ("Forex"), Contracts for Difference ("CFDs"), Indices, Options, or other financial derivatives, on "margin" carries a high level of risk, and may not be suitable for all investors. The possibility exists that you could sustain a loss of some or all of your initial investment and, therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading these markets, and seek advice from an independent financial advisor if you have any questions or doubts. Please carefully read our full "Risk Disclosure" and "Risk Disclosures for Financial Instruments & Investment Services". FXFINPRO Capital is the trading name of PFX Financial Professionals Limited, a limited liability company formed under the laws of Cyprus, registered with the Registrar of Companies in Nicosia, Cyprus, under nr. HE 237840 and regulated by the Cyprus Securities and Exchange Commission with license number 193/13.